RU2349588C2 - Способы получения производных изотиазола - Google Patents

Способы получения производных изотиазола Download PDF

Info

Publication number
RU2349588C2
RU2349588C2 RU2007106847/04A RU2007106847A RU2349588C2 RU 2349588 C2 RU2349588 C2 RU 2349588C2 RU 2007106847/04 A RU2007106847/04 A RU 2007106847/04A RU 2007106847 A RU2007106847 A RU 2007106847A RU 2349588 C2 RU2349588 C2 RU 2349588C2
Authority
RU
Russia
Prior art keywords
formula
compound
carboxylic acid
isothiazole
ureido
Prior art date
Application number
RU2007106847/04A
Other languages
English (en)
Russian (ru)
Other versions
RU2007106847A (ru
Inventor
Дэвид Б. ДЕЙМОН (US)
Дэвид Б. ДЕЙМОН
Брайан П. ДЖОУНС (US)
Брайан П. ДЖОУНС
Original Assignee
Пфайзер Продактс Инк.
Оси Фармасьютикалз, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Пфайзер Продактс Инк., Оси Фармасьютикалз, Инк. filed Critical Пфайзер Продактс Инк.
Publication of RU2007106847A publication Critical patent/RU2007106847A/ru
Application granted granted Critical
Publication of RU2349588C2 publication Critical patent/RU2349588C2/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D275/00—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings
    • C07D275/02—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings not condensed with other rings
    • C07D275/03—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings not condensed with other rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
RU2007106847/04A 2004-08-26 2005-08-02 Способы получения производных изотиазола RU2349588C2 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US60454204P 2004-08-26 2004-08-26
US60/604,542 2004-08-26

Publications (2)

Publication Number Publication Date
RU2007106847A RU2007106847A (ru) 2008-08-27
RU2349588C2 true RU2349588C2 (ru) 2009-03-20

Family

ID=36000502

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2007106847/04A RU2349588C2 (ru) 2004-08-26 2005-08-02 Способы получения производных изотиазола

Country Status (21)

Country Link
US (2) US8884025B2 (enExample)
EP (1) EP1784183B1 (enExample)
JP (2) JP5100390B2 (enExample)
KR (1) KR100893977B1 (enExample)
CN (1) CN101043888B (enExample)
AR (1) AR050613A1 (enExample)
AT (1) ATE542533T1 (enExample)
AU (1) AU2005280451B2 (enExample)
BR (1) BRPI0514667A (enExample)
CA (1) CA2578023C (enExample)
DK (1) DK1784183T3 (enExample)
ES (1) ES2378994T3 (enExample)
IL (1) IL181063A0 (enExample)
MX (1) MX2007002246A (enExample)
NO (1) NO20071319L (enExample)
PL (1) PL1784183T3 (enExample)
PT (1) PT1784183E (enExample)
RU (1) RU2349588C2 (enExample)
TW (1) TWI361688B (enExample)
WO (1) WO2006026034A2 (enExample)
ZA (1) ZA200701016B (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101043888B (zh) 2004-08-26 2010-08-11 辉瑞有限公司 制备异噻唑衍生物的方法
US8969583B2 (en) 2011-12-28 2015-03-03 Allergan, Inc. 3-phenyl-5-ureidoisothiazole-4-carboximide and 3-amino-5-phenylisothiazole derivatives as kinase inhibitors
CN103833665B (zh) * 2014-02-24 2015-09-23 杰达维(上海)医药科技发展有限公司 一种新的合成异噻唑的方法
US9353093B2 (en) 2014-10-07 2016-05-31 Allergan, Inc. Indole-1-carboxamides as kinase inhibitors
US9403803B2 (en) 2014-10-08 2016-08-02 Allergan, Inc. Indole-3-carboxamides as kinase inhibitors
US9359336B2 (en) 2014-10-09 2016-06-07 Allergan, Inc. Heterocycle-substituted pyridyl benzothiophenes as kinase inhibitors
US9371314B2 (en) 2014-10-09 2016-06-21 Allergan, Inc. Pyridyl benzothiophenes as kinase inhibitors
KR20250121146A (ko) * 2022-12-28 2025-08-11 비양 테라퓨틱스 컴퍼니 리미티드 단백질 티로신 키나제 억제제 및 이의 의약적 용도
WO2026002126A1 (zh) * 2024-06-27 2026-01-02 苏州必扬医药科技有限公司 一种蛋白酪氨酸激酶抑制剂及其眼用制剂
WO2026002137A1 (zh) * 2024-06-27 2026-01-02 苏州必扬医药科技有限公司 一种蛋白酪氨酸激酶抑制剂游离碱的晶型

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999062890A1 (en) * 1998-06-04 1999-12-09 Pfizer Products Inc. Isothiazole derivatives useful as anticancer agents
RU2002131639A (ru) * 2000-04-26 2004-07-10 Ферринг Б.В. Ингибиторы дипептидилпептидазы iv

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2408234A1 (de) * 1974-02-21 1975-09-04 Celamerck Gmbh & Co Kg Isothiazolylharnstoffe
US4059433A (en) * 1976-06-18 1977-11-22 Fmc Corporation 3-Alkoxyisothiazole derivatives as herbicides
IL72093A0 (en) * 1983-06-20 1984-10-31 Lilly Co Eli N'-substituted(3-alkyl-5-isothiazolyl)urea derivatives
HN2000000051A (es) * 1999-05-19 2001-02-02 Pfizer Prod Inc Derivados heterociclicos utiles como agentes anticancerosos
GB0010188D0 (en) * 2000-04-26 2000-06-14 Ferring Bv Inhibitors of dipeptidyl peptidase IV
CA2493701A1 (en) * 2002-07-25 2004-02-05 Pfizer Products Inc. Isothiazole derivatives useful as anticancer agents
US20060035954A1 (en) * 2004-08-11 2006-02-16 Sharma Padam N Ammonolysis process for the preparation of intermediates for DPP IV inhibitors
CN101043888B (zh) 2004-08-26 2010-08-11 辉瑞有限公司 制备异噻唑衍生物的方法

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999062890A1 (en) * 1998-06-04 1999-12-09 Pfizer Products Inc. Isothiazole derivatives useful as anticancer agents
US6235764B1 (en) * 1998-06-04 2001-05-22 Pfizer Inc. Isothiazole derivatives useful as anticancer agents
US6548526B2 (en) * 1998-06-04 2003-04-15 Pfizer Inc Isothiazole derivatives useful as anticancer agents
RU2002131639A (ru) * 2000-04-26 2004-07-10 Ферринг Б.В. Ингибиторы дипептидилпептидазы iv

Also Published As

Publication number Publication date
JP2012153705A (ja) 2012-08-16
CN101043888A (zh) 2007-09-26
BRPI0514667A (pt) 2008-06-17
MX2007002246A (es) 2007-04-20
ATE542533T1 (de) 2012-02-15
CA2578023C (en) 2012-05-15
KR100893977B1 (ko) 2009-04-20
EP1784183A4 (en) 2009-12-09
KR20070070158A (ko) 2007-07-03
JP2008510841A (ja) 2008-04-10
US20090023924A1 (en) 2009-01-22
WO2006026034A2 (en) 2006-03-09
HK1111359A1 (en) 2008-08-08
US8884025B2 (en) 2014-11-11
JP5498524B2 (ja) 2014-05-21
EP1784183B1 (en) 2012-01-25
AU2005280451A1 (en) 2006-03-09
RU2007106847A (ru) 2008-08-27
NO20071319L (no) 2007-05-29
JP5100390B2 (ja) 2012-12-19
AR050613A1 (es) 2006-11-08
DK1784183T3 (da) 2012-04-02
PT1784183E (pt) 2012-03-09
PL1784183T3 (pl) 2012-07-31
AU2005280451B2 (en) 2009-02-05
US9371298B2 (en) 2016-06-21
ES2378994T3 (es) 2012-04-19
TW200621241A (en) 2006-07-01
CN101043888B (zh) 2010-08-11
IL181063A0 (en) 2007-07-04
TWI361688B (en) 2012-04-11
WO2006026034A3 (en) 2006-06-29
ZA200701016B (en) 2008-05-28
EP1784183A2 (en) 2007-05-16
CA2578023A1 (en) 2006-03-09
US20150065726A1 (en) 2015-03-05

Similar Documents

Publication Publication Date Title
JP5498524B2 (ja) イソチアゾール誘導体の製造方法
ES2898438T3 (es) Procedimiento para producir compuesto de pirrol
US11001582B2 (en) Solid state forms of Venetoclax and processes for preparation of Venetoclax
TW513418B (en) Thiazole derivatives, their production and use
BRPI0912878A2 (pt) derivados de indazóis substituídos por fenila e benzodioxinila
JP6832946B2 (ja) キナーゼ阻害剤およびその中間体の調製方法
CN102803235A (zh) 选择性调节cb2受体的化合物
BG65104B1 (bg) Изотиазолови производни, метод за получаването им, фармацевтичен състав и използването им като противоракови средства
ES2282857T3 (es) Derivados de bifenilcarboxamida y su uso como inhibidores de quinasa p38.
BRPI0718988A2 (pt) Método para preparar um derivado de fenilalanina, e, composto
JP2017518272A (ja) 置換サイクロセリンの調製のための方法
EP3433239A1 (en) Small molecule inhibitor of the nuclear translocation of androgen receptor for the treatment of castration-resistant prostate cancer
ES2641258T3 (es) Compuesto heterocíclico bicíclico
ES2384517T3 (es) Procedimiento para la producción de una sal de un aducto de ácido de un compuesto alcalino poliacídico
CN114727977B (zh) 化合物和化合物s1p1调节剂的制备方法
JP2020193209A (ja) チアゾール誘導体の製造方法
HK1111359B (en) Processes for the preparation of isothiazole derivatives
CA3015285C (en) Small molecule inhibitors of the nuclear translocation of androgen receptor for the treatment of castration-resistant prostate cancer
WO2026104812A1 (en) Rab27 inhibitors
ES3027457A1 (es) Metodo de preparacion de zavegepant, intermedios de sintesis de zavegepant y metodos de preparacion de los mismos
HK1174335A (en) Compounds which selectively modulate the cb2 receptor

Legal Events

Date Code Title Description
MM4A The patent is invalid due to non-payment of fees

Effective date: 20180803